ImPacli

ImPacli™ is a preclinical-stage investigational drug being developed by Pharma in Silica for the treatment of solid cancers. The drug utilizes a proprietary nanoparticle drug delivery platform where paclitaxel is sequestered within biocompatible silica-based nanoparticles, approximately 40 nm in size. The therapeutic approach involves metronomic dosing—low-dose, regular administration—of paclitaxel delivered via these nanoparticles. This formulation is designed to provide direct anti-cancer effects by stabilizing microtubules while simultaneously inducing an immune system boost to enhance the body's response against tumors. The precision chemotherapy platform aims to deliver cytotoxic agents specifically to the tumor microenvironment, thereby maximizing efficacy and minimizing systemic side effects.

Brand names

ImPacli